Gastroparesis affects the spontaneous movement of muscles (motility) in the stomach. Gastroparesis can interfere with normal digestion and cause nausea, vomiting, and abdominal pain. It causes problems with blood sugar levels and nutrition. Dietary changes and medical treatment can help control the condition. Medications such as domperidone, erythromycin, anti-emetics, and others are used to treat gastroparesis condition.
The global gastroparesis treatment market is estimated to be valued at US$ 8,061.9 million in 2022 and expected to exhibit a CAGR of 3.6% during the forecast period (2022-2030).
Figure 1. Global Gastroparesis Treatment Market in Terms of Value (US$ million), By Region, 2022
To learn more about this report, request a free sample copy
An increase in the number of pipeline products is estimated to drive the global gastroparesis treatment market growth during the forecast period.
Gastroparesis Treatment Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2021 | Market Size in 2022: | US$ 8,061.9 Mn |
Historical Data for: | 2017 to 2021 | Forecast Period: | 2022 to 2030 |
Forecast Period 2022 to 2030 CAGR: | 3.6% | 2030 Value Projection: | US$ 10,726.0 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Processa Pharmaceuticals, Inc., EVOKE PHARMA , Neurogastrx, Inc., Vanda Pharmaceuticals Inc., ANI Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., Otsuka Holdings Co., Ltd., CinDome Pharma, Inc., PTC Therapeutics, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Atlantic Healthcare, and Salix Pharmaceuticals |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Figure 2. Global Gastroparesis Treatment Market Share (%), By Drug, 2022
To learn more about this report, request a free sample copy
The development of novel treatment is anticipated to propel the global gastroparesis treatment market growth over the forecast period.
An increase in the prevalence of gastroparesis leads to an increase in the demand for novel treatment products. For instance, , in January 2018, according to National Institute of Diabetes and Digestive and Kidney Diseases, out of 100,000 people, about 10 men and about 40 women have gastroparesis in United States. Thus, developing newer products will create a lucrative opportunity for market players and drive the market growth. For instance, in November 2016, researchers at Emory University School of Medicine demonstrated the positive short-term outcomes for gastric per oral endoscopic pyloromyotomy or G-POEM, a minimally invasive procedure. The novel treatment showed significant improvement in symptoms of patients with gastroparesis (diabetic gastroparesis and idiopathic gastroparesis). Novel approaches/agents under evaluation for gastroparesis, include the prokinetic ghrelin agonist relamorelin, the prokinetic serotonergic agents velusetrag and prucalopride, the anti-emetic aprepitant, and per-endoscopic pyloric myotomy procedures.
Global Gastroparesis Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
Global Gastroparesis Treatment Market: Restraint
Side effects associated with gastroparesis drugs are likely to hamper the market growth. Gastroparesis medications will vary in their side effects depending on the medication, dose, and patient’s other medical conditions. Fatigue, drowsiness, sedation, anxiety, and restlessness are some of the most prevalent side effects linked with prokinetics.
Key Players
Major players operating in the global gastroparesis treatment market include Processa Pharmaceuticals, Inc., EVOKE PHARMA, Neurogastrx, Inc., Vanda Pharmaceuticals Inc., ANI Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., Otsuka Holdings Co., Ltd., CinDome Pharma, Inc., PTC Therapeutics, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Atlantic Healthcare, and Salix Pharmaceuticals.
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients